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Stroke is associated with high disability and mortality burdens worldwide, but there are few ef-
fective and widely available therapies. There is therefore a need to develop treatments that pro-
mote the repair and regeneration of ischemic brain tissue. In this regard, a population of adult 
stem cells-called endothelial progenitor cells (EPCs)-has been identified in peripheral blood 
that could provide novel approaches in regenerative medicine for curing patients with acute 
ischemic stroke. There is accumulating evidence that EPCs can repair damaged endothelia and 
attenuate the development and progression of atherosclerosis. Also, EPCs can be recruited in 
response to acute ischemic events and participate in reparative vasculogenesis. Most studies 
related to EPCs have involved patients with cardiovascular diseases, and there is emerging evi-
dence that EPCs represent a risk marker and a potential therapeutic agent in cerebrovascular 
disease. Here we review the characteristics and biology of EPCs in cerebrovascular disease and 
discuss the challenges that must be addressed to clarify the role and therapeutic applicability of 
EPCs in cerebrovascular disease.  J Clin Neurol 2008;4:139-147
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Introduction 
 
Stroke is an important cause of mortality and disability world-
wide,
1 with an associated high socioeconomic impact, but the 
only effective curative therapeutic approaches are thrombo-
lytic treatments, which have narrow time windows and li-
mited availabilities. Furthermore, stroke eventually leads to 
tissue necrosis and possibly to irreversible impairment of 
brain function.
2 Therefore, repair processes after cerebral 
ischemia should be investigated in order to develop thera-
peutic strategies for promoting neurorecovery. Endothelial 
repair and neovascularization are possible in the adult brain 
recovering from ischemic stroke, and could include both an-
giogenesis and vasculogenesis-combining these two processes 
could be one of the most promising therapeutic strategies for 
stroke.  
Endothelial progenitor cells (EPCs) are a type of adult 
stem cell that has been actively investigated. These immature 
hematopoietic endothelial cells circulate in peripheral blood 
(PB).
3 EPCs counteract ongoing risk-factor-induced endo-
thelial cell injury, and in response to acute hypoxia are mo-
bilized from bone marrow (BM) to PB and participate in 
endothelial cell repair and regeneration and also in tissue 
neovascularization.
4 Experimental and human studies have 
shown that EPCs participate in neovascularization processes 
in ischemic organs, and hence their regulation could have 
therapeutic applications in various vascular diseases.
5-7 
Increased cardiovascular risk factors and the presence of 
atherosclerosis are associated with dysfunction and reduced 
numbers of EPCs.
4,8-11 Moreover, a low number of EPCs is an 
independent risk factor for future cardiovascular events.
12,13 
Coronary artery disease and cerebrovascular disease (CVD) 
are two sides of the same coin with similar etiologies that 
result in endothelial damage and arteriosclerosis. Although 
EPCs have been studied in cardiac disease and might be 
surrogate markers of vascular function, there have been only 
a few observation studies on the contribution of EPCs to 
CVD.
14-20 Biological assays of EPCs in stroke might reveal 
the specific mechanisms of ischemic lesions and predict their 
severities and outcomes. In this review, we discuss the cur- 
 
 
 
 
EPCs in Cerebrovascular Disease 
  140 J Clin Neurol 2008;4:139-147
rent developments in EPC research with special emphasis on 
CVD, including in the risks of stroke, acute stroke, and 
chronic stroke. We also discuss the challenges of transplant-
ing EPCs as a treatment for stroke. 
 
Biology 
 
BM contains a mobile pool of nonhematopoietic cells that 
express various markers of tissue-committed stem cells that 
could migrate to the peripheral circulation and exert benefi-
cial effects on regeneration.
21-23 Their mobilization, recruit-
ment, and homing mechanisms are regulated by various che-
mokines and cytokines, and several physiological and patho-
logical conditions can influence the number of circulating 
progenitor cells. EPCs constitute a population of purified cells 
that originate directly from the hemangioblast, a common 
precursor of hematopoietic and endothelial cells.
24 Such EPCs 
most likely coexpress specific endothelial and stem/progen-
itor markers such as vascular endothelial (VE)-cadherin and 
CD133, and whilst being extremely rare in PB they are 
markedly increased after vascular trauma.
25 EPCs isolated 
from PB differentiate into a mature endothelial phenotype 
based on their microscopic appearance, functional character-
istics {uptake of acetylated low-density lipoprotein (acLDL) 
and nitric oxide synthesis}, and expression of cell-surface 
markers {E-selectin, von Willebrand factor (vWF), VE-cad-
herin, platelet-endothelial cell adhesion molecule, and c-kit} 
associated with loss of CD133 expression.
25  
BM cells circulating in the PB increase in number during 
tissue injury and are chemoattracted to the ischemic tissues. 
It has been shown that BM progenitor cells can be released 
from BM/tissue niches, circulate, and finally be chemoat-
tracted to ischemic tissue in an SDF-1/CXCR4-dependent 
manner.
26 In a manner characteristic of circulating BM cells, 
EPCs are mobilized during ischemia or exogenously by stim-
ulation with cytokines, and contribute to neovascularization 
of ischemic tissues.
7,27-29 An experimental study found that 
the number of CD34
+ EPCs gradually increased for 7 days 
after a stroke and remained significantly above the prestroke 
baseline to day 14, returning to baseline by day 30.
14 
EPCs can be isolated from PB in sufficient quantities for 
harvesting, and after their ex vivo expansion they can be ad-
ministered systemically to enhance neovascularization. Thus, 
circulating EPCs have the potential for vascular repair after 
injury. Vascular progenitor cells have been shown to incor-
porate into areas of active vascular growth in animal models 
of hind-limb, myocardial, and cerebral ischemia,
7,27 indicat-
ing their therapeutic potential either by providing endothelial 
cells for new vessel growth or through secretion of angiogenic 
growth factors that activate neighboring cells. The suggested 
regenerative potential of EPCs has prompted clinical studies 
of the following two hypotheses: (1) patients with lower 
numbers of EPCs have a higher risk of vascular diseases, 
and (2) patients with ischemic events would benefit from 
EPC transplantation. 
 
Characteristics and Measurement 
 
EPCs are maturating cells derived from immature stem cells, 
and hence they possess functional and structural character-
istics of both stem cells and mature endothelial cells. During 
their development, EPCs gradually lose stem-cell character-
istics and progressively gain endothelial-cell characteristics. 
EPCs should be quantified with caution due to their hetero-
geneity. Two quantification techniques have been reported. 
The first is flow cytometry, in which cells are labeled with 
fluorescent antibodies to EPC cell-surface antigens (see Ta-
ble 1) and subsequently counted with a flow cytometer. The 
rarity of EPCs in PB makes it necessary to reduce the noise-
to-signal ratio.
30 Isolated BM-derived EPCs represent more 
Table 1. Characteristics of early endothelial progenitor cells (EPCs), endothelial outgrowth cells (EOCs), and neuronal outgrowth cells 
(NOCs) 
  Early EPCs  EOCs  NOCs 
Morphology CFU,  spindle  Cobblestone  Palisading 
Growth pattern in vitro  Early growth  Late outgrowth  Late outgrowth 
Antigen expression 
 
CD34, KDR, Tie-2, CD34, CD31, vWF,  
VE-cadherin, CD14, CD45 
KDR, CD31, CD36 
vWF, VE-cadherin, Tie-2 
Nestin, Vimentin, Tuj-1,   
Dcx, NG2 
acLDL uptake and lectin binding  Positive  Positive  Negative 
Incorporation into HUVECs  Good  Better  Possible 
Tube formation  None  Yes  None 
Cytokine expression  High level  Low level  Low level 
Population Heterogeneous  Homogeneous  Homogeneous 
Angiogenic potential  Good  Good  Possible 
Neurogenic potential  None  None  Good 
CFU: colony-forming units, HUVECs: human umbilical vein endothelial cells, vWF: von Willebrand factor, Tuj-1: beta III tubulin, Dcx:
doublecortin, acLDL: acetylated low-density lipoprotein, VE-cadherin: vascular endothelial-cadherin.     
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immature cells, expressing the early hematopoietic marker 
CD133,
31 and their phenotype is in general CD133
+/CD34
+/ 
VEGFR-2
+/VE-cadherin
-.
32 In contrast, EPCs isolated from 
PB obviously lose CD133 and gradually start to express CD31, 
VE-cadherin, c-Kit, vWF, CD146, and CXCR4.
3,32 A com-
bination of CD34 and VEGR2 cell-surface markers in a mo-
nonuclear population has recently been recommended as the 
best choice for EPC identification.
33,34 The second technique 
is cell culture (see Fig. 1), in which PB-derived mononuclear 
cells (PBMNCs) are cultured for several days in conditions 
that selectively favor the growth of EPCs. These conditions 
include using gelatin-coated plates and adding endothelial 
growth factors to the culture medium. Since EPCs have to be 
viable and able to respond to the culture conditions, culture-
based quantification of EPCs also depends on their function. 
EPCs forming colony-forming units (CFU) from the third 
day after plating are typically counted after 7 to 28 days. 
Further testing to confirm the endothelial phenotype of the 
cells involves the uptake of acLDL, binding of Ulex euro-
paeus lectin, and binding of specific antibodies.
3,19,20 In con-
trast to flow cytometry, culturing methods depend on EPC 
function, and indirectly measure the number of EPCs. This 
difference means that the results from the two widely used 
techniques cannot be directly compared,
34 making some sort 
of standardization desirable. 
Interpreting the results from the ever-increasing number 
of reports on EPC biology has been hampered by a lack of 
corroborated methods for precisely identifying EPCs. Some 
investigators have used flow cytometry to estimate EPC 
numbers,
8,18,29 whereas others refer to the number of CFU. 
Since the number of circulating EPCs represents a dynamic 
balance between their production induced by chronic or 
acute stimuli and their consumption in damaged areas, per-
forming flow cytometry at a small number of time points 
during acute ischemia is of limited usefulness. There is 
emerging evidence that EPC functional properties are better 
represented by the number of CFU than by the number of 
EPCs.
4,15,17,19,20 Whereas EPC function is critical for endo-
thelial maintenance and repair, the number of CFU might 
indicate the cumulative vascular risk in ischemia.   
Since Asahara et al. first reported the existence of EPCs in 
PB,
3 several studies have found significant heterogeneity 
among EPC populations in in vitro cultures. At least three 
types of EPC have been described (Table 1). PBMNCs con-
tain cells termed “early EPCs” that share some endothelial 
but also monocytic characteristics and a restricted capacity 
for expansion.
35 Recent studies have also shown the existence 
of a more promising population that originate from BM, cir-
culate in PB, and whose morphology and proliferation pattern 
differs from the EPCs reported by Asahara et al.
3 So-called 
endothelial outgrowth cells appear after 2 to 3 weeks of cul-
ture, rapidly replicate from multiple cells, and form into mo-
nolayers with a cobblestone-like morphology and a high pro-
liferation capacity.
19,35,36 Current data suggest that this popu-
Fig. 1. Serial images of human peripheral-blood mononuclear cells (PBMNCs) cultured in endothelial growth media (EGM) to produce 
various types of progenitor cells. Phase-contrast images show the maturation of PBMNCs obtained from stroke patients during the culture
immediately (A) and 7 days (B and C) after plating. Long-term cultures produced a heterogeneous population of cells (D) and led to a 
cobblestone (E) or palisading (E) outgrowth of cells. Scale bars: 30 μm (C), 60 μm (A and B), and 150 μm (D-F). 
A  B  C
D  E  F 
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lation of outgrowing cells is a subset of true EPCs deriving 
from BM that exhibit the potential for vascular repair after 
injury. More recently, we have also isolated and cultured two 
types of outgrowing cells obtained from the PB of patients 
with acute stroke.
19 These cells were named endothelial or 
neuronal outgrowth cells (NOCs), according to their mor-
phological characteristics and protein or gene expression pro-
files. Both types of outgrowing cells maintained their proli-
ferative capacities during a culture period of 3 months. Al-
though numerous reports have described the clinical signifi-
cance of circulating EPCs, there are few data supporting their 
stem or progenitor status-namely, the ability to give rise to 
proliferating, functional endothelial cells such as outgrowing 
cells. We have performed studies validating the number of 
outgrowth cells as a potential marker representing the number 
of circulating progenitor cells.
19,20 
 
EPC Profiles in Patients at Risk of CD 
 
Circulating EPCs could be a marker of endothelial function 
and cardiovascular risk. EPC numbers are significantly de-
creased in subjects with elevated serum cholesterol, hyper-
tension, and diabetes, and in smokers.
37,38 Measurements of 
flow-mediated brachial-artery reactivity also revealed a sig-
nificant relation between endothelial function and the number 
of EPCs, supporting a role for EPCs in the maintenance of 
endothelial integrity.
4 Endothelial cell injury and endothelial 
dysfunction are predictors of the risk of vascular events, pro-
viding stimuli for the development of atherosclerotic plaques.
8 
Consistent with this hypothesis, cardiovascular risk factors-
as well as coronary, cerebral, and peripheral atherosclerosis-
have been associated with low EPC numbers,
4,8-11,15,39 which 
has also been shown to represent an independent risk factor 
for future cardiovascular events.
12,13 Moreover, depletion of 
CD34
+/KDR
+ EPCs was found to be an independent predic-
tor of early subclinical atherosclerosis in healthy subjects.
39  
There have been a few observation studies on the contri-
bution of EPCs to cerebral atherosclerosis and stroke. Table 
2 summarizes data from previous studies related to circulat-
ing EPCs in CVD. In patients with prior stroke, the number 
of circulating CD34
+/KDR
+ EPCs is negatively correlated 
with carotid intima-media thickness, and is an independent 
risk factor for increased carotid intima-media thickness and 
the presence of carotid plaques.
16 Furthermore, stroke pa-
tients with lower than normal numbers of CD34
+/KDR
+ 
EPCs had a significantly greater carotid intima-media thick-
ness and a significantly higher prevalence of carotid plaques. 
In addition, there was a strong negative correlation between 
Table 2. Summary of previous studies on circulating EPCs in cerebrovascular disease
Reference  Parameter  Stroke risk  Prognosis  Risk or burden  Other 
Taguchi et al., 200414  CD34+ cells  Serial changes in   
acute stroke (peak,  
D7; baseline, D30) 
Many EPCs: CBF increase  Few EPCs: DM, being 
older 
Few EPCs: many  
infarctions 
 
Ghani et al., 200515  CFU Acute  stroke  < stable  
stroke << controls 
ND Few  EPCs: being  
older 
 
Lau et al., 200716  CD34+/KDR+ 
cells 
Chronic stroke   
<< controls 
Stroke with few EPCs:  
atherosclerosis progression 
Few EPCs: high   
carotid IMT and   
plaque formation 
 
Sobrino et al., 200717  CFU  ND  Large increase in EPC   
numbers: good outcome,   
reduced infarct growth,   
improvement of NIHSS score 
ND EPC  change   
during 1 week  
after stroke 
Yib et al., 200818  CD31/CD34   
CD62E/CD34  
KDR/CD34 
Acute stroke >> at-risk 
controls 
Many EPCs: improvement   
of NIHSS score (D21) 
Many EPCs: recurrent   
ischemic stroke, any cause   
of death, or NIHSS score   
≥12 (D90) 
ND Prognosis 
Jung et al., 200819  EOCs, NOCs  Acute stroke >> at-risk   
controls > normal   
controls 
ND Many  EPCs: high   
NIHSS score 
Source for cell   
therapy 
CFU Acute  stroke   
<< chronic stroke   
< healthy controls 
ND Few  EPCs: LAA, high   
HbA1c level 
EPC dysfunction: 
LAA 
Chu et al., 200820 
 
OC Acute  stroke   
>> chronic stroke   
> healthy controls 
ND Many  EPCs: high   
NIHSS score 
 
ND: not determined, IMT: intima-media thickness, NIHSS: National Institutes of Health Stroke Scale, LAA: large-artery atherosclerosis, OC:
outgrowth cells, CBF: cerebral blood flow, DM: diabetes mellitus.     
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the numbers of circulating CD34- and CD133-positive cells 
and the presence of old infarction.
14 Analysis of patients with 
cerebral artery occlusion revealed a significant positive cor-
relation between circulating CD34- and CD133-positive cells 
and regional blood flow in areas of chronic hypoperfusion, 
suggesting that EPCs contribute to the homeostasis and re-
pair of the cerebral circulation and maintenance of brain me-
tabolism.
14 The reduction in the number of EPCs appears to 
result from a decreased production and an enhanced degene-
ration of EPCs during the atherosclerotic process. Moreover, 
risk factors for atherosclerosis might directly influence the 
mobilization and survival of EPCs by impairing the bioa-
vailability of nitric oxide. These findings support the notions 
that EPCs play an important part in the pathogenesis of 
atherosclerotic disease and that the measurement of EPCs 
could improve risk stratification. 
 
EPC Profiles in Acute Stroke 
 
EPCs are mobilized from BM during acute ischemia and 
contribute to the neovascularization of ischemic tissues. Acute 
myocardial infarction is associated with mobilization and a 
rapid increase in circulating EPCs.
28 In the same line of acute 
cardiovascular events, vascular trauma such as coronary by-
pass grafting or burn injury induces a rapid but transient 
mobilization of VEGFR2
+/AC133
+ EPCs.
29 Clinical trials 
assessing the therapeutic potential of BM-derived mononu-
clear cells (a rich source of immature cells including EPCs) 
in hind-limb
40,41 and cardiac
42 ischemia have yielded promis-
ing results. BM-derived immature cells have also been shown 
to participate in neovascularization of ischemic brain after 
experimentally induced stroke.
43 Immature cells, including 
CD34
+ cells, have been shown to contribute to vasculature 
maintenance, not only as a pool of EPCs but also as the 
source of growth/angiogenesis factors. Stroke involves a 
complicated cascade of events involving cerebral ischemia; 
altered blood flow; disruption, inflammation, neuronal ne-
crosis, and apoptosis of the blood-brain barrier; and neu-
rological dysfunction.
44-46 Which of these mechanisms are 
involved in the mobilization of EPCs is not clear, but vas-
cular trauma and tissue ischemia appear to facilitate EPC 
mobilization to the peripheral pool, in part by the release of 
cytokines and vascular endothelial growth factor. 
In initial observation studies, Taguchi et al.
14 measured 
CD34
+ cells by flow cytometry in 25 patients with an is-
chemic stroke. They found that the values peaked after 7 
days and returned to baseline after 30 days. Ghani et al.
15 
reported that the number of clusters of rapidly adhering cells 
was decreased after stroke and in “stable CVD” compared to 
in controls free of vascular disease. They found that being 
older and the presence of CVD are generally independently 
related to a lower number of EPCs, with no significant in-
crease in EPC numbers being observed in the weeks after 
acute or stable stroke. These conflicting results are probably 
due to a lack of corroborated methods that can precisely 
identify EPCs. 
We recently analyzed the characteristics of EPCs in acute 
stroke patients, focusing on their differences according to the 
pathogenetic mechanism.
20 We found that the number of CFU 
was lower in acute stroke patients than in control subjects, 
and much lower in patients with large-artery atherosclerosis 
than in those with cardioembolism. Our data are consistent 
with a previous report
15 that EPC numbers differed signifi-
cantly among acute stroke, stable stroke, and control subjects, 
and extend those observations by suggesting that CFU anal-
ysis can improve the understanding of stroke pathophysio-
logy. We also demonstrated a relationship between the known 
surrogate markers for chronic vasculopathy, with the HbA1c 
level being an independent predictor for fewer CFU in a 
multivariate analysis. A previous study found that the num-
ber of EPCs was significantly related to the HbA1c and 
blood sugar levels in diabetics, and that improving glycemic 
control can significantly increase the number of EPCs.
47 Our 
data showing that the degree of glycemic dysregulation affects 
EPC function are in line with this previous report. On the 
other hand, the outgrowing cells appeared in most of the 
stroke patients but only rarely in control subjects. It is pos-
sible that immediate endothelial or neural damage induced 
by stroke induces a compensatory BM overproduction of pro-
genitor cells for damage repair. It should also be emphasized 
that indexes for neurological damage, such as the NIHSS 
(National Institutes of Health Stroke Scale) score and in-
farct volume, were associated with the number of outgrowth 
cells. Our results indicated that the numbers of CFU and out-
growing cells represent markers of the accumulated vascular 
risk and response to ongoing tissue damage, respectively. 
 
EPC as a Marker of Stroke Prognosis 
 
But do higher EPC numbers during the acute stage reverse 
the consequences of ischemia and improve prognosis? In 
observational studies involving patients with myocardial in-
farction, higher numbers of EPCs indeed relate to a better 
prognosis, more myocardial salvage,
48 viability, and perfu-
sion,
49 and more collaterals in the ischemic zone.
50 Human 
and animal model studies have shown that EPCs play a major 
role in angiogenesis and regeneration of ischemic brain tissue. 
However, the impact of the number of circulating EPCs on 
clinical outcomes after stroke remains uncertain. A recent 
clinical study found that the number of circulating EPCs was  
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significantly higher in patients with acute ischemic stroke 
than in at-risk control subjects, and that the magnitude of this 
difference is directly related to the functional outcome.
18 One 
prospective study involving 48 stroke patients showed that 
the EPC increase during the first week was independently 
associated with a good outcome at 3 months.
17 This favora-
ble effect on the primary variable was supported by the re-
duction of infarct growth and neurological improvement at 
days 7 and 90. These findings are in line with experimental 
and human studies suggesting that EPCs mediate endothelial 
cell regeneration and neovascularization, and that EPCs par-
ticipate in the cerebral neovascularization processes present 
in the adult brain after ischemia. Further prospective inves-
tigations of patients with CVD to establish a prognostic value 
of EPCs in ischemic stroke would be very useful. 
 
EPC as a Potential Source  
for Cell Therapy 
 
Mature nervous tissue has been considered incapable of cell 
renewal and structural remodeling for a long time, especially 
in mammals. However, stem cells are likely to replenish cells 
that are lost by physiological turnover, as well as in patho-
logical conditions. It has recently been shown that appro-
priate in vitro and in vivo stimuli can induce adult somatic 
stem cells obtained from BM and PB to differentiate into 
neural-like cells.
51-53 There have been intensive efforts over 
the past decade to develop therapeutic strategies for promoting 
revascularization of ischemic tissues. Since arteriogenesis 
and angiogenesis can be triggered by ischemia as native 
compensatory mechanisms,
54 the discovery that EPCs are 
present in human PB raises the possibility of EPCs-mediated 
therapeutic neovascularization as a novel option for the treat-
ment of ischemic diseases. The isolation and expansion of 
EPCs might be specifically useful for identifying therapeutic 
approaches targeting the progression and recurrence of stroke. 
Asahara et al.
3 found transplanted EPCs in the endothelium 
of newly formed vessels in previously ischemic animal limbs. 
In other animal experiments, EPC administration also result-
ed in increased blood flow in ischemic zones and a decrease 
in limb loss.
6 In experimentally induced cardiac ischemia, 
administration of progenitor cells resulted in neovasculari-
zation and a smaller infarcted area, although the involved 
mechanisms remained unclear.
55  
Brain repair after stroke is a formidable task, because the 
lesions are often large and involve cells of all types, resulting 
in the loss of many complex synaptic connections. EPC 
transplantation has been used to minimize the effects of is-
chemic stroke in animal models.
56-58 Taguchi et al.
56 dem-
onstrated that the systemic administration of human CD34-
positive cells accelerated neovascularization in the cerebral 
ischemic zone 48 h after stroke in a mouse model. This 
treatment also increased neurogenesis and improved func-
tional indexes in these animals. Similarly, human cord blood 
administered intravenously to rats after stroke was able to 
enter the brain and dispersed in the ischemic brain microen-
vironment, resulting in improved functional recovery com-
pared to controls.
57 BM-derived cells have also been shown 
to participate in neovascularization processes in the adult 
brain of mice following ischemia.
58 Neurological functions 
after chronic cerebral ischemia were considerably better in 
rats intracerebrally transplanted with PB stem cells than in 
vehicle-treated control rats. PB stem cells transplanted into 
rats were observed to migrate toward infarcted cerebral zones 
and to differentiate into neurons, glial cells, and endothelial 
cells, thus enhancing neuroplasticity in the ischemic brain.
59 
The intravenous injection of PB stem cells into rats early 
after focal cerebral ischemia reduced lesion volumes and 
improved regional cerebral blood flow and cognitive func-
tions.
60 The use of cells derived from PB or BM, including 
EPCs, provides two main advantages over the use of other 
cell types: (1) it avoids ethical limitations because there is 
no need to work with fetal or embryonic tissue, and (2) 
there is a host of experience on the use of hematopoietic 
progenitor cells in hemato-oncology research, and therefore 
there is considerable knowledge of treatment tolerability and 
side effects. Furthermore, neovascularization and neurogenesis 
might be tightly linked in the brain. A rich vascular environ-
ment, along with the generation of other nurturing neuronal 
mediators by EPCs (e.g., VEGF, FGF2, and IGF-1) enhances 
subsequent neuronal progenitor migration to the damaged 
area, followed by their maturation and survival when EPCs 
have stimulated the formation of increased vascular channels. 
We have previously described the in vitro expansion and 
characterization of two types of progenitor cells from the PB 
of acute stroke patients.
19 These cells are referred to as NOCs, 
in accordance with their morphological characteristics and 
protein or gene expression profiles. If neural progenitors could 
be isolated from human PB in sufficient quantities to permit 
harvesting, theoretically they would offer unlimited thera-
peutic possibilities. NOCs express immature neuronal markers 
over at least five passages, while maintaining rates of ex-
pansion characteristic of progenitor cells. Furthermore, the 
expressions of these markers are maintained in subclones 
obtained from these cells, and these subclones can be in-
duced to undergo uniform differentiation into neurons in a 
chemically defined medium. Since PB-derived neural pro-
genitor cells can be isolated without risk or potential side 
effects, their storage, expansion, and differentiation abilities 
makes them valuable candidates for transplantation therapy.  
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Moreover, we found that intracerebral grafts of purified un-
modified neural progenitor cells survived, migrated, and dif-
ferentiated into neuronal phenotypes in ischemic rat brains.
19 
The exploitation of adult stem cells with neuronal charac-
teristics-preferably obtained from easily accessible tissues-
represents the best way of approaching cell therapy in stroke 
patients. 
 
Future Challenges of EPC  
Research in CD 
 
In future studies on the role of EPCs in stroke, several caveats 
should be borne in mind. First, we consider that the greatest 
current challenge in the field of EPC research is the lack of 
appropriate cell-surface markers specific for the identifi-
cation of EPCs. Second, the laboratory technique of EPC 
quantification should be standardized as much as possible, 
and the timing of blood sampling (directly after the stroke or 
in the stable phase) should be considered, since the values 
obtained could differ between the acute and chronic phases. 
Third, the role of EPCs in the pathophysiology of CVD is no 
more than speculative at present. Therefore, it would be wise 
to further investigate the role of EPCs in different forms of 
stroke before planning clinical trials involving EPC injec-
tions. We also believe that the remarkable healing potential 
already demonstrated by EPC transplantation in experiment-
ally induced stroke will become a clinical reality. However, 
we consider that clinical trials at this stage are premature and 
could be counterproductive. We suggest that this issue would 
be best progressed by standardizing certain aspects of basic 
research, especially the outcome measures, to facilitate com-
parisons between studies. In addition, long-term studies are 
required to determine whether cell-enhanced recovery is sus-
tained, and to elucidate the tumorigenic potentials of cells. 
Furthermore, we must learn how to influence the patholog-
ical tissue environment and how this is related to repair. Other 
critical challenges include ensuring adequate characteriza-
tion, manufacture, and quality control of cells, standardizing 
cell preparation protocols, and developing more definitive 
markers for stem cells. Identification of cell-surface markers 
for true stem cells would allow stem cell populations to be 
enriched or purified directly from heterogeneous cells.   
EPCs or stem cells isolated from elderly stroke patients 
might retain dysfunctional characteristics, and therefore have 
reduced abilities to augment therapeutic regeneration. The 
expansion of cells in culture is an attractive strategy because 
it induces the potentiation of dysfunctional stem cells. Aside 
from these issues concerning ex vivo manipulation, consi-
derable time is required to culture sufficient adult stem cells 
ex vivo to meet therapeutic requirements, and thus there is a 
need for an off-the-shelf supply of adult stem cells in the form 
of a cell bank that would allow physicians and surgeons to 
use stem cells directly at the point of care, rather than limit-
ing their use to elective procedures. 
 
Conclusion 
 
EPCs hold great promise in CVD research, both as a marker 
for an increased risk of stroke and as a therapeutic agent after 
stroke. EPCs could change pathophysiological and therapeutic 
concepts, which will hopefully improve clinical treatments 
in vascular neurology. Recent work has provided a better 
understanding of these cells compared to what was known a 
decade ago. However, despite the promising results from 
various investigations (including our own), larger prospec-
tive studies should investigate this possible causation in order 
to confirm their role and applicability. Future studies should 
focus on establishing definitive markers of EPCs, better isola-
tion methods, and the in-depth mechanisms underlying their 
beneficial effects. 
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